EUVIMEDEUVIMED entdecken
Crossref

Routine Prenatal cfDNA Screening for Autosomal Dominant Single-Gene Conditions

Sophie Adams iD, Olivia Maher Trocki, Christina Miller, Courtney Studwell, Meghan Bombalicki, Lori Dobson, Sofia Horan, Jordan Sargent, Michael Duyzend, Kathryn J Gray, Stephanie Guseh, Louise Wilkins-Haug

Clinical Chemistry · 2025

DOI: 10.1093/clinchem/hvae189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, 2025. Verfasst von Sophie Adams und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Fetal Medicine and Reproductive Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Genetic screening has advanced from prenatal cell-free DNA (cfDNA) screening for aneuploidies (cfDNA-ANP) to single-gene disorders (cfDNA-SGD). Clinical validation studies have been promising in pregnancies with anomalies but are limited in the general population.

Methods

Chart review and laboratory data identified pregnancies with cfDNA-SGD screening for 25 autosomal dominant conditions at our academic center. Screening was identified as routine by International Classification of Diseases (ICD) 10 codes and chart review. Ultrasound anomalies or known family history of a condition on the panel were excluded. Retrospective chart review investigated test concordance, outcomes, and phenotypes. Results cfDNA-SGD was completed for 3480/37 050 (9.4%) pregnancies, of which 2745 (78.9%) were for routine screening. Fourteen (0.51%, 14/2745) had high-risk results defined as pathogenic/likely pathogenic (P/LP) variants: 6 (0.22%) likely fetal variants, and 8 (0.29%) maternal variants with 50% risk for fetal inheritance. Diagnostic testing detected 6/6 fetal and 6/8 maternal cfDNA-SGD variants (2/8 pregnant individuals declined testing but had clinical features on physical exam). Variants were detected in 11/14 pregnancies/newborns and in 9/14 (64.3%) parents/gamete donors. There were no false positives identified by cfDNA-SGD; however, 2 variants were discrepantly classified between the cfDNA-SGD and diagnostic testing laboratories. All pregnancies had normal imaging and 9 had mild postnatal phenotypes. Three terminated pregnancy following diagnostic testing.

Conclusions

Our study demonstrated that 0.51% of routine cfDNA-SGD was high risk, prompting comprehensive evaluation for pregnancies and parents. Routine cfDNA-SGD allowed for early identification and intervention, but raises counseling challenges due to variable expressivity, limited genotype–phenotype correlations, and discrepant variant classification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell-Free Nucleic AcidsHumansFemalePregnancyRetrospective StudiesPrenatal DiagnosisAdultGenetic TestingGenes, DominantNoninvasive Prenatal Testing

Substanzen

Cell-Free Nucleic Acids

Autor:innen und Institutionen

  • Center for Fetal Medicine and Reproductive Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
  • Center for Advanced Molecular Diagnostics, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
  • Division of Genetics and Genomics and Maternal Fetal Care Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.
  • Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
  • Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, United States.
  • Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, United States.

ORCID-Profile: Sophie Adams

Zitieren

APA

Adams, S., Trocki, O. M., Miller, C., Studwell, C., Bombalicki, M., Dobson, L., Horan, S., Sargent, J., Duyzend, M., Gray, K. J., Guseh, S., & Wilkins-Haug, L. (2025). Routine Prenatal cfDNA Screening for Autosomal Dominant Single-Gene Conditions. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvae189

Vancouver

Adams S, Trocki OM, Miller C, Studwell C, Bombalicki M, Dobson L, et al. Routine Prenatal cfDNA Screening for Autosomal Dominant Single-Gene Conditions. Clinical Chemistry. 2025. doi:10.1093/clinchem/hvae189

BibTeX
@article{Adams2025,
  author = {Adams, Sophie and Trocki, Olivia Maher and Miller, Christina and Studwell, Courtney and Bombalicki, Meghan and Dobson, Lori and Horan, Sofia and Sargent, Jordan and Duyzend, Michael and Gray, Kathryn J and Guseh, Stephanie and Wilkins-Haug, Louise},
  title = {Routine Prenatal cfDNA Screening for Autosomal Dominant Single-Gene Conditions},
  journal = {Clinical Chemistry},
  year = {2025},
  doi = {10.1093/clinchem/hvae189}
}
Kostenlos starten →